Chapter 34 — Key Takeaways

The one sentence

Analysis characterizes a sample; a supply chain characterizes a product — and no quantity of the first substitutes for the second.

The three questions people collapse into one

A vial can be 98% pure by HPLC and contain far less peptide by mass than its label states, because counterion (commonly trifluoroacetate), residual water, and salts make up the remainder. Purity and content are different numbers, and a certificate frequently reports only the first. This is the most practically valuable point in the chapter.

What each technique establishes, and what it does not

Mass spectrometry measures mass-to-charge ratio with high accuracy. A peptide's exact mass follows from its composition, so a measured mass strongly constrains identity; tandem MS (MS/MS) fragments the peptide and reads sequence from the fragment masses.

• Proves: something in the sample has the expected mass — and, with MS/MS, the expected sequence.
• Does not prove: that this is the only species present, in what proportion, or that the vial you hold matches the sample tested.
• Structurally cannot detect: isomeric and some near-isobaric substitutions, and D-amino acid substitution, which changes no mass at all.

HPLC separates components by differential partitioning between mobile and stationary phases. Purity is usually reported as the target peak's area as a percentage of total peak area. Four honest limitations:

1. Co-elution — two species emerging together appear as one peak.
2. The detector defines the universe — UV absorbance at a given wavelength misses species lacking the chromophore. What is not detected is not counted as an impurity; it is not counted at all.
3. Peak area is not mass — response factors differ between compounds.
4. Deletion sequences differing by one residue may not separate (Ch 32 §32.3) — which is why they are the characteristic impurity and the one the standard assay is least able to see.

Amino acid analysis hydrolyzes and quantifies the constituent amino acids, establishing composition, not sequence — the distinction Chapter 1's Sanger case study drew, and it still holds. Edman degradation (requires a free N-terminus) and MS/MS establish order. AAA's other major role is quantitative: it is a primary method for peptide content.

Sterility and endotoxin are separate tests for separate hazards

Sterility asks whether anything is alive in the vial; endotoxin asks whether anything ever was. — the formulation coined in Chapter 19

Endotoxin is bacterial cell-wall lipopolysaccharide. It survives sterilization by heat or filtration, is not removed by processes designed to kill or exclude microbes, and produces fever and inflammatory responses when injected. It has no visual signature. Endotoxin testing is routinely not performed outside regulated manufacture.

Reading a certificate of analysis

Six things a CoA can establish, properly done: identity by MS; purity by HPLC with the method stated; peptide content by quantitative assay; water content; counterion content; and, if performed, sterility and endotoxin results.

Four things it cannot establish — and these matter more:

1. That the certificate corresponds to the vial in your hand. It describes a sample, potentially from a different batch, potentially supplied by someone else.
2. Anything about handling after testing — temperature excursion, aggregation, degradation in transit.
3. Anything the method did not look for. A CoA reporting HPLC purity says nothing about endotoxin.
4. Its own authenticity. A document is trivially copied or fabricated.

A certificate of analysis is a claim about a sample. It is not a property of a vial.

What independent testing has found — and why there is no percentage

Independent testing of unregulated peptide products has reported the categories this book has named: wrong identity, incorrect content relative to label, presence of unexpected species, and inadequate documentation.

This book does not state a failure rate, because no defensible one exists. Samples are not randomly drawn; the market changes constantly; methods and thresholds vary between programs; and negative results are less likely to be published. Any percentage would be a number without a denominator.

And note: "we don't know the rate" is not reassuring. It means exposure cannot be calculated. Uncertainty is not safety.

Why analysis is not a substitute for oversight

Even flawless analysis of a submitted sample leaves:

• Batch-to-batch variation — you tested that batch.
• Chain of custody — the vial you received is not the vial tested.
• Handling and storage after testing.
• Aseptic filling — a process guarantee no end-product test can replace. You cannot test sterility into a product: the test is destructive, so it samples, and sampling has low power against low-level contamination.
• Everything after administration — no baseline, no monitoring, no adverse-event pathway, no one accountable.

The regulated supply chain is not primarily a testing regime; it is a system of documented process control, accountability, and recourse.

Testing a sample cannot make an unregulated product equivalent to a regulated one, and nothing in this chapter should be read as suggesting otherwise.

Monograph versus GMP

Pharmacopeias (USP, Ph. Eur.) publish monographs specifying what a substance must meet. GMP is a system of documented process control, personnel qualification, environmental monitoring, batch records, and change control.

A monograph defines the specification; GMP is how you know the process reliably produces material meeting it. The first is checked by testing a sample. The second is verified by inspecting a system, and cannot be reconstructed after the fact.

The ratings from this chapter

The habit to build

When you meet an analytical claim, ask three questions:

1. Which of the three questions does this answer — identity, purity, or content?
2. Percent of what, measured how, seen by which detector?
3. What is this a claim about — a sample, or the object in front of me?

Most claims do not survive those three questions. The ones that do are saying something genuinely useful, and still not saying anything about the ten rows below the molecule in §34.1's table.